Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Buparlisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 8/20 | 0.98 |
| ▸ | PIK3R1 known ✓ | P27986 | 5/20 | 0.98 |
| ▸ | PIK3CG known ✓ | P48736 | 3/20 | 0.98 |
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 0.98 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 2/20 | 0.98 |
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 11/20 | 0.98 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.98 |
| ▸ | PRKDC | P78527 | 2/20 | 0.98 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.98 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.98 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.98 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.70 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.70 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.70 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buparlisib SCHEMBL29412438 | 1.00 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL18528952 | 1.00 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29493083 | 1.00 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL896994 | 0.99 | MTOR (0.96) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL146956 | 0.99 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29351351 | 0.99 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29350945 | 0.99 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29387968 | 0.99 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL896966 | 0.98 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| SCHEMBL19460575 | 0.97 | MTOR (0.96) | MTORPIK3CAPIK3R1PIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377818-B2 | Method of treating glioma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-10130629-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2018-11-20 | — | — | US | disclosed |
| EP-3040333-B1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | NOVARTIS AG (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-20180064709-A1 | PHARMACEUTICAL COMBINATIONS | BEIJING NOVARTIS PHARMA CO. LTD. (CN) | 2018-03-08 | — | — | US | disclosed |
| EP-3273959-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9637468-B2 | Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2964200-B1 | FORMULATIONS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017050111-A1 | CRYSTAL FORM AND PREPARATION METHOD OF 5-[2,6-DI(4-MORPHOLINYL)-4-PYRIMIDINYL]-4-(TRIFLUOROMETHYL)-2-PYRIDINAMINE HYDROCHLORIDE | 苏州晶云药物科技有限公司 | 2017-03-30 | — | — | WO | disclosed |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-9474534-B2 | Formulations of organic compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150246897-A1 | Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS PHARMA AG (CH) | 2015-09-03 | — | — | US | disclosed |
| EP-2912030-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | Novartis AG (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| WO-2014136048-A1 | FORMULATIONS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014064058-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | NOVARTIS AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2621908-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044727-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-04-05 | — | — | WO | disclosed |
| US-20120059005-A1 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) AN ANTIDIABETIC COMPOUND FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064709-A1 | PHARMACEUTICAL COMBINATIONS | PKD1, SLC5A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PIK3CA 2617/4885PIK3R1 3764/4885PIK3CG 3661/4885 |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, TYMS | PIK3CA 879/4885PIK3R1 4209/4885PIK3CG 2133/4885 |
| US-20150246897-A1 | Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | PAH, QDPR, NISCH | PIK3CA 890/4885PIK3R1 3293/4885PIK3CG 689/4885 |
| US-10130629-B2 | Pharmaceutical combinations | PKD1, SLC5A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PIK3CA 2617/4885PIK3R1 3764/4885PIK3CG 3661/4885 |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | PIK3CA 602/4885PIK3R1 4000/4885PIK3CG 1738/4885 |
| US-20120059005-A1 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) AN ANTIDIABETIC COMPOUND FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | PIK3CA, PDPK1, PIK3CB | PIK3CA 1/4885PIK3R1 79/4885PIK3CG 10/4885 |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, MTOR, RICTOR | PIK3CA 104/4885PIK3R1 7/4885PIK3CG 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.